Mast cell tryptase stimulates DLD-1 carcinoma through prostaglandin- and MAP kinase-dependent manners

J Pharmacol Sci. 2005 Aug;98(4):450-8. doi: 10.1254/jphs.fpj05002x. Epub 2005 Aug 10.

Abstract

We found that striptease-positive mast cells were abundant in the invasive front of human colon adenocarcinoma by examining 30 cases. Because tryptase has been suggested to be the agonist proteinase for protease-activated receptor-2 (PAR-2), we investigated the effects of stimulation of PAR-2 by tryptase on the cell signaling and proliferation of DLD-1, a human colon carcinoma cell line. PAR-2 stimulation by tryptase induced the increase in [Ca(2+)](i), which was desensitized by the prior application of PAR-2 activating peptide (AP). The proliferative responses of DLD-1 to tryptase and PAR-2 AP were associated with the phosphorylation of MEK and MAP kinase. Inhibition of MEK by PD98059 completely inhibited the proliferation-enhancing effects of tryptase and PAR-2 AP as well as phosphorylation of MAP kinase. Moreover, tryptase and PAR-2 AP stimulated the production of prostaglandin E2 and the inhibition of prostaglandin synthesis by indomethacin or NS398 resulted in the complete inhibition of the proliferative responses to tryptase and PAR-2 AP. Furthermore, the tryptase-stimulated proliferation of DLD-1 was concentration-dependently inhibited by nafamostat mesilate, a specific inhibitor of tryptase. These results as a whole indicated that tryptase has proliferative effects on DLD-1 through cyclooxygenase- and MAP kinase-dependent manners acting on PAR-2 by its proteolytic activity.

MeSH terms

  • Benzamidines
  • Calcium / analysis
  • Calcium / metabolism
  • Carcinoma / pathology
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Colonic Neoplasms / metabolism*
  • Colonic Neoplasms / pathology
  • Cyclooxygenase Inhibitors / pharmacology
  • Cytosol / metabolism
  • Dinoprostone / metabolism
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacology
  • Flavonoids / pharmacology
  • Guanidines / pharmacology
  • Humans
  • Immunohistochemistry
  • Indomethacin / pharmacology
  • Mast Cells / enzymology*
  • Mitogen-Activated Protein Kinase 3 / metabolism
  • Mitogen-Activated Protein Kinases / metabolism*
  • Nitrobenzenes / pharmacology
  • Phosphorylation / drug effects
  • Prostaglandins / metabolism*
  • Receptor, PAR-2 / agonists
  • Receptor, PAR-2 / metabolism
  • Serine Endopeptidases / pharmacology*
  • Sulfonamides / pharmacology
  • Tryptases

Substances

  • Benzamidines
  • Cyclooxygenase Inhibitors
  • Enzyme Inhibitors
  • Flavonoids
  • Guanidines
  • Nitrobenzenes
  • Prostaglandins
  • Receptor, PAR-2
  • Sulfonamides
  • N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases
  • Serine Endopeptidases
  • Tryptases
  • Dinoprostone
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
  • Calcium
  • Indomethacin
  • nafamostat